Analiza and Bio-Cord are reaching a strategic agreement to promote the Umbilical Cord Stem Cells preservation service in Spain. Thanks to this collaboration, Analiza patients can obtain information in all their medical centres and laboratories.
As part of their continuous vocation for innovation and offering the latest developments, Analiza is broadening their portfolio, including the service for the preservation of Umbilical Cord Stem Cells of new-borns.
Umbilical Cord Stem Cells
Umbilical Cord Stem Cells have been used for 35 years in more than 80 oncological diseases, medullary failures, immunodeficiencies, autoimmune diseases and hemoglobinopathies.
In addition, there are also research and clinical trials in various stages that will be able to treat other diseases in the future such as diabetes, Alzheimer’s, sclerosis, Parkinson’s, cardiac diseases, tissue regeneration, etc., among many other lines of investigation.
The extraction of blood from the umbilical cord for the preservation of its stem cells is a fast and completely painless process for both mother and baby and is carried out at the moment of birth.
It is also possible to preserve the umbilical cord tissue, which contains a particular type of unique stem cells (mesenchymal cells) with great potential in regenerative medicine.
Bio-Cord
Bio-Cord, is the leading private stem cell bank for this service in Spain. As well as being chosen by the principal health insurers, they have more than 19 years’ experience, preserving 75,000 samples of umbilical cord stem cells.
For Bio-Cord each client is unique and therefore they have an individual logistic for each sample: analyzing it, processing and preserving it at a single point in order to obtain the best quality of each sample.
If you would like further information on Bio-Cord’s services for umbilical cord stem cell preservation, as well as their special prices for your health insurance, you can contact them through
www.analizalab.com | 914 297 541 | [email protected]
www.bio-cord.es | 911 794 062 | [email protected]
¿Quieres recibir noticias como ésta en tu email?
Suscríbete a la newsletter